Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Squamous Cell Carcinoma of Head and Neck AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: Squamous Cell Carcinoma of Head and Neck AND Cancer. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001023-80 Sponsor Protocol Number: 26 Start Date*: 2015-02-09
    Sponsor Name:Danish Head and Neck Cancer Group (DAHANCA)
    Full Title: DAHANCA 26. A phase II unblinded, randomized study of paclitaxel and capecitabine with or without cetuximab as first line treatment of recurrent or metastatic squamous cell head and neck cancer (HN...
    Medical condition: Recurrent or metastatic squamous cellular head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001951-20 Sponsor Protocol Number: UCL/06/053 Start Date*: 2008-03-12
    Sponsor Name:University College London
    Full Title: A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Locally advanced or metastatic squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063569 Metastatic squamous cell carcinoma LLT
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013317-10 Sponsor Protocol Number: GEN211 Start Date*: 2009-12-15
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN
    Medical condition: Non-Curable Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002647-29 Sponsor Protocol Number: ELECTROCHEMO-1 Start Date*: 2014-02-12
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Clinical trial to evaluate the efficacy and tolerability of electrochemotherapy for palliative treatment in patients with head and neck squamous cell carcinoma
    Medical condition: head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    16.1 10042613 - Surgical and medical procedures 10019190 Head and neck therapeutic procedures HLGT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001928-29 Sponsor Protocol Number: GORTEC2015-02 Start Date*: 2015-07-07
    Sponsor Name:GORTEC
    Full Title: Phase II randomized trial comparating two concomitant administration of radiotherapy with cisplatin in patients with not operated or inoperable squamous cell carcinoma of the head and neck or with...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014396-43 Sponsor Protocol Number: HN001 (TEMHEAD) Start Date*: 2010-02-09
    Sponsor Name:Medical School Hannover
    Full Title: A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)
    Medical condition: Patients with metastatic or local recurrenct squamous carcinoma of the head and neck (HNSCC) who have measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastat...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001802-25 Sponsor Protocol Number: 28-03-2007 Start Date*: 2008-10-27
    Sponsor Name:Johann-Wolfgang Goethe-Universität
    Full Title: An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascul...
    Medical condition: Patients of both gender are eligible for this study in case they present with the diagnosis of a primary squamous cell carcinoma of the head & neck after Magnevist-enhanced MRI, are scheduled for t...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002097-61 Sponsor Protocol Number: DAHANCA 19 Start Date*: 2007-07-26
    Sponsor Name:Danish Head and Neck Cancer Group
    Full Title: Undersøgelse af betydningen af EGFr antistoffet Zalutumumab for effekten af strålebehandling til patienter med primært planocellulært hoved-hals karcinom.
    Medical condition: Squamous cell carcinomas of the Head and Neck treated with primary radiotherapy/kemoradiotherapy and randomized to the IMP in question (zalutumumab).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002765-36 Sponsor Protocol Number: IEO38 Start Date*: 2014-03-23
    Sponsor Name:Istituto Europeo di Oncologia
    Full Title: SIB –IMRT using a modulated accelerated fractionation for head and neck cancer patients
    Medical condition: head and neck squamous cell carcinoma eligible for a curative treatment with radiotherapy and Cetuximab
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001816-39 Sponsor Protocol Number: SANTAL Start Date*: 2016-07-15
    Sponsor Name:GORTEC
    Full Title: Phase III randomized trial comparating concomittant administration of radiotherapy with cisplatin versus radiotherapy only for treatment of sinuses tumors and salivary glands
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001780-30 Sponsor Protocol Number: GORTEC 2006-01 Start Date*: 2007-02-28
    Sponsor Name:UCL Saint Luc 1200 Bruxelles
    Full Title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique
    Medical condition: Cet essai s'adresse à des patients porteurs d'un carcinome épidermoïde de la tête et du cou en rechute locale ou en situation métastatique et qui ne peuvent plus bénéficier d'un traitement curatif
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004280-22 Sponsor Protocol Number: RECET Start Date*: 2010-07-23
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie
    Full Title: Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck
    Medical condition: Preirradiated patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003592-64 Sponsor Protocol Number: UCL/17/0560 Start Date*: 2018-03-16
    Sponsor Name:University College London
    Full Title: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamo...
    Medical condition: recurrent/metastatic head and neck squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000615-15 Sponsor Protocol Number: EMR200052-013 Start Date*: 2008-07-14
    Sponsor Name:Merck KGaA
    Full Title: Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuxima...
    Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002472-17 Sponsor Protocol Number: Hx-EGFr-202 Start Date*: 2007-06-19
    Sponsor Name:Genmab A/S
    Full Title: An Open-labelled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients ...
    Medical condition: Non-Curable Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) LT (Completed) HU (Prematurely Ended) EE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017943-32 Sponsor Protocol Number: 871 Start Date*: 2010-05-31
    Sponsor Name:Antwerp University Hospital
    Full Title: Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer
    Medical condition: Histologically confirmed squamous cell carcinoma of the head and neck which qualifies for definitive treatment with chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003636-36 Sponsor Protocol Number: UCL/17/0396 Start Date*: 2019-01-08
    Sponsor Name:University College London
    Full Title: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Recurrent/metastatic head and neck squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-002782-12 Sponsor Protocol Number: OOI-001 Start Date*: 2007-08-08
    Sponsor Name:National Institute of Oncology
    Full Title: Open, uncontrolled, non-commercial Clinical Trial of induction chemotherapy with Cetuximab, Docetaxel, Cisplatin, 5FU followed by Cetuximab + radiotherapy in the responders in locally advance...
    Medical condition: locally advanced squamous cell carcinoma of head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000582-39 Sponsor Protocol Number: GEN205 Start Date*: 2008-09-18
    Sponsor Name:Genmab A/S
    Full Title: An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcino...
    Medical condition: Non-Curable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000254-21 Sponsor Protocol Number: MO39839 Start Date*: 2021-04-20
    Sponsor Name:University Hospital Essen
    Full Title: Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) in local head and neck squamous cell carcinoma
    Medical condition: local squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:05:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA